Literature DB >> 12093301

Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.

Ron L Akehurst1, John E Brazier, Nigel Mathers, Caroline O'Keefe, Eva Kaltenthaler, Anne Morgan, Maria Platts, Stephen J Walters.   

Abstract

OBJECTIVES: To identify the impact of irritable bowel syndrome (IBS) on health-related quality of life (HR-QOL), time off work and the utilisation and cost of health services.
DESIGN: A case-control study was undertaken matching patients with IBS and controls. Quality-of-life information was collected using the Medical Outcomes Study 36-item Short Form (SF-36) health survey, EuroQOL instrument (EQ-5D) and IBS Quality-of-Life (IBS-QOL) instruments. Data on time off work was also collected. National Health Service (NHS) resource use in primary and secondary care was estimated by review of general practitioner (GP) and hospital records over a 12-month period.
SETTING: Recruitment was from six GPs' surgeries in the Trent Region of the United Kingdom. PARTICIPANTS: 161 patients with IBS, as defined by the Rome Criteria I were recruited. These were compared with 213 controls matched for age, sex and social characteristics. MAIN OUTCOME MEASURES: SF-36 and EQ-5D scores; mean number of days off work; mean NHS costs per person during the 12-month study period.
RESULTS: Patients with IBS had considerably lower HR-QOL than controls. They scored worse in all dimensions of the SF-36 and the EQ-5D and they had more time off work. On average patients with IBS cost the NHS 123 UK pounds (95% confidence interval: 35 UK pounds to 221 UK pounds, 1999 values) more per year than individuals in the control group (p = 0.04).
CONCLUSIONS: IBS affects patients through reduced quality of life, more time off work and greater healthcare utilisation than a control group of patients without IBS. The difference in quality of life was pronounced and unusual in that it was influential in every dimension of both the SF-36 and the EQ-5D.

Entities:  

Mesh:

Year:  2002        PMID: 12093301     DOI: 10.2165/00019053-200220070-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  18 in total

Review 1.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

2.  Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

Authors:  B A Hahn; S Yan; S Strassels
Journal:  Digestion       Date:  1999 Jan-Feb       Impact factor: 3.216

3.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 4.  Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants.

Authors:  W G Paterson; W G Thompson; S J Vanner; T R Faloon; W W Rosser; R W Birtwhistle; J L Morse; T A Touzel
Journal:  CMAJ       Date:  1999-07-27       Impact factor: 8.262

5.  The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).

Authors:  A Haycox; T Einarson; A Eggleston
Journal:  Scand J Gastroenterol Suppl       Date:  1999

6.  Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting.

Authors:  R Harper; J E Brazier; J C Waterhouse; S J Walters; N M Jones; P Howard
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

Review 7.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

8.  Irritable bowel syndrome in the general population.

Authors:  R Jones; S Lydeard
Journal:  BMJ       Date:  1992-01-11

9.  Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan.

Authors:  R J Schlemper; S D van der Werf; J P Vandenbroucke; I Biemond; C B Lamers
Journal:  Scand J Gastroenterol Suppl       Date:  1993

Review 10.  Clinical economics review: irritable bowel syndrome.

Authors:  N E Wells; B A Hahn; P J Whorwell
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

View more
  63 in total

Review 1.  Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D.

Authors:  Stephen J Walters; John E Brazier
Journal:  Qual Life Res       Date:  2005-08       Impact factor: 4.147

2.  Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI.

Authors:  Leah Kleinman; Anne Kilburg; Gerardo Machnicki; Randall Faull; Rowan Walker; Ramesh Prasad; Patrice Ambuehl; Udo Bahner; Mary Kay Margolis
Journal:  Qual Life Res       Date:  2006-09-14       Impact factor: 4.147

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

5.  Prevalence, impact and attitudes toward lower gastrointestinal dysmotility and sensory symptoms, and their treatment in Canada: A descriptive study.

Authors:  Richard H Hunt; Surinder Dhaliwal; Gervais Tougas; Carmen Pedro; Jean-Francois Labbé; Heidi Paul; Michael Ennamorato
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

6.  Cultural adaptation and application of the IBS-QOL in China: a disease-specific quality-of-life questionnaire.

Authors:  Wen-Wei Huang; Fu-sheng Zhou; Donald M Bushnell; Chiaka Diakite; Xiao-huan Yang
Journal:  Qual Life Res       Date:  2007-04-12       Impact factor: 4.147

Review 7.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

8.  Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria.

Authors:  Xavier Badia; Fermin Mearin; Agustin Balboa; Eva Baró; Ellen Caldwell; Mercedes Cucala; Manuel Díaz-Rubio; Arturo Fueyo; Julio Ponce; Mentse Roset; Nicholas J Talley
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 9.  New approaches to the medical treatment of irritable bowel syndrome.

Authors:  Driss Berrada; Katia Canenguez; Tony Lembo
Journal:  Curr Gastroenterol Rep       Date:  2003-08

Review 10.  Current perspectives on the diagnosis and treatment of functional esophageal disorders.

Authors:  Roy Dekel; Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.